Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients

[1]  Timothy A. Chan,et al.  The hallmarks of successful anticancer immunotherapy , 2018, Science Translational Medicine.

[2]  R. Herbst,et al.  A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers , 2018, Nature Communications.

[3]  M. Hummel,et al.  Immunohistochemical Study of Mitosis-regulatory Proteins in Gastroenteropancreatic Neuroendocrine Neoplasms , 2018, AntiCancer Research.

[4]  Steven M. Anderson,et al.  Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden , 2018, Journal of Immunotherapy for Cancer.

[5]  Steven J. M. Jones,et al.  The Immune Landscape of Cancer , 2018, Immunity.

[6]  Daniel F. Hayes,et al.  20‐Year Risks of Breast‐Cancer Recurrence after Stopping Endocrine Therapy at 5 Years , 2017, The New England journal of medicine.

[7]  K. Bloom,et al.  Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  L. Zitvogel,et al.  Trial watch: Immune checkpoint blockers for cancer therapy , 2017, Oncoimmunology.

[9]  F. Hodi,et al.  Monitoring immune-checkpoint blockade: response evaluation and biomarker development , 2017, Nature Reviews Clinical Oncology.

[10]  C. Morrison,et al.  Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing , 2016, Oncotarget.

[11]  M. Kriegsmann,et al.  What is better/reliable, mitosis counting or Ki67/MIB1 staining? , 2016, Translational lung cancer research.

[12]  Brittany N. Lasseigne,et al.  RNA sequencing-based cell proliferation analysis across 19 cancers identifies a subset of proliferation-informative cancers with a common survival signature , 2016, bioRxiv.

[13]  Keunchil Park,et al.  Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial , 2016, The Lancet.

[14]  P. Keegan,et al.  FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1 , 2016, The oncologist.

[15]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[16]  Xiaoying Shen,et al.  Expression of MTA2 and Ki-67 in hepatocellular carcinoma and their correlation with prognosis. , 2015, International journal of clinical and experimental pathology.

[17]  Audrey Andrews.  Treating with Checkpoint Inhibitors-Figure $1 Million per Patient. , 2015, American health & drug benefits.

[18]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[19]  Mark Gardner,et al.  Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors. , 2018, The Journal of molecular diagnostics : JMD.

[20]  J. Sørensen,et al.  Clinical impact of ki-67 labeling index in non-small cell lung cancer. , 2013, Lung cancer.

[21]  J. Samet,et al.  Food and Drug Administration , 2007, BMJ : British Medical Journal.